anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to improved (simplified/easier, more stable and more reproducible) methods for identifying carbohydrate composition (e.g. from complex carbohydrate mixtures) and determining carbohydrate mixture composition patterns (e.g. glycosylation patterns) and based on advanced internal standards to use novel fluorescent dye junctionsThe present invention relates to methods for automated determination and/or identification of carbohydrate and/or carbohydrate mixture composition pattern analysis, and methods for automated carbohydrate mixture composition pattern analysis, based on the use of at least a first and a second fluorescent marker for labeling migration/retention time alignment standards and samples or different samples, respectively, wherein at least one fluorescent dye is a compound as defined herein, furthermore, the present invention relates to methods for calibrating multi-wavelength fluorescence detection systems, as well as calibration systems or calibration standards, and novel compounds described as being suitable for use in calibration. The invention further relates to a kit or system for determining or identifying a pattern of composition of a carbohydrate mixture and a kit or system for determining and/or identifying a pattern of composition of a carbohydrate mixture. Further, there is provided a carbohydrate dye conjugate comprising a dye as defined herein for use in a method according to the invention. The dye used to form the carbohydrate dye conjugate has the following formula a or B:
2096441 9208480 PCTABS00013 A new heterodimeric form of TGF-.beta. is described. This 25 KD  molecule is active in an in vitro assay of inhibition of epithelial cell growth. The protein may be isolated from bone. When reduced, the protein elutes in two peaks by RP-HPLC. In immunoblots, the reduced protein from the earlier eluting peak reacts predominately with antibodies directed against TGF-.beta.3, while reduced protein from the later eluting peak reacts predominately with antibodies directed against TGF-.beta.2. The N-terminal amino acid sequence and immunoreactivity of the native protein are consistent with a heterodimer of TGF-.beta.2 and TGF-.beta.3.
PURPOSE:To provide a cardiotonic agent containing cholic acid and its sodium salt and exhibiting cardiac artery dilating action. CONSTITUTION:The objective agent can be prepared by using deoxycholic acid of formula I or deoxycholic acid sodium salt of formula II as main component, mixing with pharmacologically allowable additive and forming in the form of medicine by conventional method. It can be used as suspension, syrup, tablet, powder, injection, suppository, etc. It is administered at a rate of 30-500 mg/day for a person of 60kg body-weight in about 3 divided doses. Sodium salt of cholic acid is easily soluble in water and exhibits an especially excellent drug action. The chenodeoxycholic acid of formula III, the glycocholic acid of formula IV and their sodium salts can be used as active components for another cardotonic agent.
INTRODUCTION: The rise in opioid use for managing chronic and oncologic pain has led to a significant increase in opioid-induced constipation (OIC) that impacts patient quality of life and pain management.
AREAS COVERED: In this study, emerging therapies for OIC were criticized for refining advancements and novel treatment options. Key topics included the efficacy of peripherally acting mu-opioid receptor antagonists (PAMORAs) such as methylnaltrexone, naloxegol, and naldemedine, which specifically target opioid-induced gut dysfunction. Other treatment options, including intestinal secretagogues like lubiprostone and linaclotide, selective 5-HT receptor agonists such as prucalopride, and emerging adjunctive therapies like transcutaneous electrical nerve stimulation (TENS) and electroacupuncture were mentioned. Current guidelines from the American Gastroenterological Association (AGA) and the European consensus were criticized.
EXPERT OPINION: Experts stress the importance of a stepwise approach to managing OIC, considering patient-specific factors and the efficacy of various treatments. While PAMORAs have demonstrated effectiveness in improving bowel function, their high cost and lack of extensive head-to-head comparisons with traditional laxatives are significant concerns. Emerging therapies and adjunctive treatments offer promising results but require further validation through rigorous studies. Future research should focus on long-term outcomes, cost-effectiveness, and comparative effectiveness to better address the complex needs of patients with OIC and refine treatment protocols.
This study will be a randomized control trial and will be conducted in National stadium and Ravians Basketball club Lahore. The study will be completed within the time duration of six months. Non-probability convenience sampling technique will be used to collect the data. The sample size of total 24 athletes will be taken in this study. The participants will be divided into two groups i-e, one group will receive circuit training and other group will receive trunk stabilization exercises.

Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes. The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
In recent years, polymeric hydrogels have been employed to investigate cancer cell-extracellular matrix (ECM) interactions in vitro. In the context of breast cancer, cancer cells are known to degrade the ECM using matrix-metalloproteinases (MMPs) to support invasion resulting in disease progression. Polymeric hydrogels incorporating MMP-cleavable peptides have been employed to study cancer cell invasion, however, the approaches employed to incorporate these peptides often change other hydrogel properties. This underscores the need for decoupling hydrogel properties while incorporating MMP-cleavable peptides. Herein, we report structurally decoupled hyaluronic acid (HA) hydrogels formulated using varying ratios of a biologically sensitive MMP-cleavable peptide and an insensitive counterpart (Dithiothreitol (DTT) or polyethylene glycol dithiol (PEGDT)) to study MMP-mediated metastatic breast cancer cell invasion. Rheological, swelling ratio, estimated mesh size, and permeability measurements showed similar mechanical and physical properties for hydrogels crosslinked with different DTT (or PEGDT)/MMP ratios. However, their degradation rate in the presence of collagenase correlated with the ratio of MMP-cleavable peptide. Encapsulated metastatic breast cancer spheroids in HA hydrogels with MMP sensitivity exhibited increased invasiveness compared to those without MMP sensitivity after 14 days of culture. Overall, such structurally decoupled HA hydrogels provide a platform to study MMP-mediated breast cancer cell invasion in vitro.
A vaccine for immunizing dogs against infectious canine hepatitis comprises an apathogenic, avirulent, living, duck-embryo-modified infectious canine hepatitis virus (I.C.H.). Modified I.C.H. is produced by serially passing pathogenic and virulent I.C.H. virus through duck embryos a plurality of times and especially at least 37 times.  Preferably the I.C.H. virus is serially passed successively through ferrets a plurality of times and through duck embryos a plurality of times.  The above vaccine may be mixed with a living, chickembryo-modified, canine distemper virus.  The vaccines may be mixed with a stabilizing menstruum containing sucrose and casein hydrolysate.  Compatible bacterial antigens such as inactivated cultures of Leptospirae, Streptococci, Salmonella and Brucellae may also be present.
Disclosed herein are the compounds shown below and methods of their synthesis. The value m is a positive integer. R comprises an alkyl chain or an alkoxy chain. Each X comprises a metal binding group. Each E is a methoxy group or comprises a biomolecule reactive group or a residue thereof. E optionally comprises a protecting group. The value n is a positive integer. The value p is zero or one. Y is OCH 3 , OH, NH 2 , or COOH.
PURPOSE: Aromatase inhibitors (AI) block estrogen synthesis and are used as long-term adjuvant treatment for breast cancer in postmenopausal women. AI use can be associated with weight gain that can lead to increased cardiometabolic risk. The response to anti-obesity medications (AOM) in patients using AI has yet to be studied. We sought to investigate weight loss outcomes of AOM in patients taking AI for breast cancer treatment.
METHODS: This is a matched retrospective cohort study of breast cancer survivors on AI using AOM (AOM/AI group). We compared their weight loss outcomes with a group of female patients with obesity, without a history of breast cancer or AI use, on AOM (AOM group). The primary endpoint was total body weight loss percentage (TBWL %) at the last follow-up. We performed mixed linear regression models, including diabetes status at baseline, to assess associations between use of AOM with/without AI with total body weight loss percentage (TBWL%).
RESULTS: We included 124 patients: 62 in the AOM/AI group (63.6 ± 10 years, body mass index [BMI] 34.3 ± 7.1 kg/m2) and 62 in the AOM group (62.8 ± 9.9 years, BMI 34.6 ± 6.5 kg/m2). The mean time of follow up was 9.3 ± 3.5 months, with no differences among the two groups. The AOM/AI group had a lower TBWL% compared to the AOM group at the last follow-up -5.3 ± 5.0 vs. -8.2 ± 6.3 (p = 0.005). The results remained significant after adjusting for diabetes status (p = 0.0002). At 12 months, the AOM/AI group had a lower TBWL% compared to the AOM group 6.4 ± 0.8% vs. 9.8 ± 0.9% (p = 0.04). The percentage of patients achieving ≥ 5%, ≥ 10%, and ≥ 15% of weight loss at 12 months was greater in the AOM compared to the AOM/AI group. Although the weight loss response was suboptimal, patients in the AOM/AI group had improvement in fasting glucose, glycated hemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol.
CONCLUSIONS: The use of AI in breast cancer survivors is associated with less weight loss response to AOM compared to patients without breast cancer history and who do not take AI. Studies are needed to assess the mechanisms behind the differential weight loss response to AOM in women taking AI.
Embodiments described herein relate to implantable medical devices (IMDs) and methods for use therewith. Such a method includes enabling a communication capability of an IMD during a message alert period and monitoring for a message while the communication capability is enabled during the message alert period. In response to receiving a message during the message alert period, there is a determination whether the message is valid or invalid. If the message is invalid, the message is ignored, and an invalid message count is incremented. A further message is monitored for during the message alert period occurs, when the invalid message count has not yet reached a corresponding invalid message count threshold. The communication capability of the IMD is disabled for a disable period, when the invalid message count reaches the corresponding invalid message count threshold. If a valid message is received, the IMD acts upon information included therein.
Urodynamic studies routinely involve instillation of iohexol (OmnipaqueTM), a low osmolality contrast agent, into the bladder followed by fluoroscopic imaging to assess for reflux or variant anatomy of the genitourinary system. Recently, sulfur hexafluoride lipid-type A microspheres (LumasonTM), an ultrasound contrast agent, has been approved in the United States for intravesicular administration in the pediatric population. Contrast enhanced voiding urosonography (CEvUS) is being increasingly utilized in the place of voiding cystourethrograms, with the major advantages being decreased (zero) radiation for the patient, as well as decreased cost. Given the similarity in procedure between urodynamic studies (UDS) and voiding cystourethrograms, we hypothesize that a urodynamic study may be performed with contrast enhanced ultrasound instead of fluoroscopy. We plan to continue enrollment from our feasibility study and perform an efficacy study by recruiting a group of 105 patients under the age of 18, who are willing to undergo their normally schedule UDS using CEvUS to image the study in place of fluoroscopy. The UDS typically consists of two cycles of bladder filling and voiding; we intend replace the use of fluoroscopy and iohexel with ultrasound and sulfur hexafluoride lipid-type A microspheres. This will decrease the time commitment and eliminate radiation exposure for the patient. Data to be analyzed will include images from the study and patient/caregiver preference. Results from the ceVUS images will be compared to images obtained during previous tests imaged with fluoroscopy from the same patients currently enrolled in this study. Bladder shape and morphology, bladder neck configuration and performance, structure of the urethra, presence and degree of vesicoureteral reflux, and active voiding images will all be compared to fluoroscopy images from previous studies. The purpose of the study is to demonstrate that ceVUS is effective as an imaging technique for urodynamic studies, with an ultimate goal of using ceVUS instead of fluoroscopy in all urodynamic and voiding studies in order to decrease pediatric radiation exposure. The hypothesis is that ceVUS will be as effective for imaging urodynamics studies as fluoroscopy.
The study aims to assess the effectiveness of a mobile app-based tool in improving conditioning, mobility, and physical therapy performance among patients recovering from orthopedic surgery, particularly hip fracture fixation, spinal fusion, and total knee/hip arthroplasty. The app sets reminders for in-bed conditioning exercises, with difficulty levels adjusted based on patient feedback. The prospective, single-arm pilot study will enroll patients over 65 years old with adequate cognitive status and a mobile phone. Patient performance on the app, satisfaction metrics, and physical therapy outcomes will be evaluated, along with feedback from physical therapists. The study is conducted through the Yale New Haven Health System, with plans to enroll 15 patients initially and subsequently expand to a randomized controlled trial with 50 participants in each arm. The goal is to improve outcomes in this population, characterized by poor mobility, morbidity, and mortality rates, by supplementing inpatient rehabilitation with targeted, app-prompted exercises.
Participants in Cohort 4, Arm 4B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of sodium chloride for injection placebo was 5 mg/m\^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
Drug: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
Hypothermia is a relatively rare condition in pregnancy and has been associated with fetal bradycardia. The management of maternal hypothermia resulting in fetal bradycardia presents a challenging dilemma for healthcare professionals. Currently, no evidence exists to advise on the duration of this condition before obstetric interventions are necessary for a safe outcome for both mother and infant. We discuss a case of a 26-year old primigravida with a gestational age of 32 weeks, who presented with clinical urosepsis, resulting in severe hypothermia up to 32 degrees Celsius. Active warming measures were taken and intravenous antibiotic treatment was started. Fetal evaluation on the cardiotocogram showed prolonged bradycardia (90 BPM) prompting consideration of a cesarean section. However, after multidisciplinary consultation, conservative treatment was proposed since there were no other signs of fetal hypoxia; no decelerations, good variability and accelerations. The patient started to show clinical improvement and had a body core temperature of 36 degrees Celsius after approximately 60 h of active rewarming measures. Fetal heartrate baseline normalized as the maternal temperature raised. Subsequently the patient was discharged in good clinical condition and had an uncomplicated vaginal delivery of a healthy newborn at term. In conclusion, when fetal bradycardia occurs due to maternal hypothermia, in the absence of signs for fetal hypoxia on the cardiotocogram, treatment of the underlying maternal condition instead of immediate obstetrics intervention is the best clinical option. This strategy aims to address the underlying cause of maternal hypothermia and consequently fetal bradycardia while ensuring the well-being of both mother and fetus and preventing unnecessary premature delivery.
Geriatric: Healthy volunteers were treated with a regimen of 2 mg taken before each of 3 meals. There were no significant differences in repaglinide pharmacokinetics between the group of patients <65 years of age and a comparably sized group of patients ≥65 years of age (See PRECAUTIONS, Geriatric Use).

Pediatric: No studies have been performed in pediatric patients.

Gender: A comparison of pharmacokinetics in males and females showed the AUC over the 0.5 mg to 4 mg dose range to be 15% to 70% higher in females with type 2 diabetes. This difference was not reflected in the frequency of hypoglycemic episodes (male: 16%; female: 17%) or other adverse events. With respect to gender, no change in general dosage recommendation is indicated since dosage for each patient should be individualized to achieve optimal clinical response.

Race: No pharmacokinetic studies to assess the effects of race have been performed, but in a U.S. 1-year study in patients with type 2 diabetes, the blood glucose-lowering effect was comparable between Caucasians (n=297) and African-Americans (n=33). In a U.S. dose-response study, there was no apparent difference in exposure (AUC) between Caucasians (n=74) and Hispanics (n=33).
PURPOSE:To obtain the titled ulcer agent containing a specific fraction obtained by extracting rhizome of a plant of the genus Iris of the family Iridaceae with an alcohol to give an essence and extracting the essence with an ether as an active ingredient. CONSTITUTION:An anti-peptic ulcer remedy containing a fraction (solubility; extremely soluble in chloroform, soluble in methanol and ethyl ether and slightly soluble in ethyl acetate and benzene; total nitrogen amount; <=1.0wt.%; color reaction: positive in anthrone-sulfuric acid reaction. Liebermann reaction, etc.) obtained by extracting rhizome of a plant of the genus Iris of the family Iridaceae (.e.g Lris tectorum MAXIM, Iris florentina L., I. germanica L., I. pallida LAMARK, etc.) with an alcohol to give an essence and extracting the essence with an ether as an active ingredient Oral drugs such as powder, granule, tablet, etc., are preferable as the dosage form. An oral dose is preferably 1-1,000mg/kg/day and preferably administered dividedly three times daily.
Participants in this group will self-administer 50 mg etanercept injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
<P>PROBLEM TO BE SOLVED: To provide a cosmetic composition containing a polysaccharide (levan) which exerts an excellent cell-proliferating, skin moisturizing and skin irritation- alleviating effects and is produced by microbes free of stability- and safety- related problems.  <P>SOLUTION: The cosmetic composition contains the polysaccharide (levan) which is isolated and purified from microbes known to produce levan using sucrose as a substrate, such as Rahnella aquatilis, Zymomonas mobilis and Pseudomonas aurantiaca. Levan is isolated and purified from media in which the microbes have been cultured, and dried. The levan extracted and purified from the microbes is shown to have an excellent skin-moisturizing effect through a measurement of its moisturizing effect, no toxicity through a cytotoxicity test and a skin irritation-alleviating effect through a skin irritation test employing a three-dimensional bioartificial skin and a human patch test. The composition is also shown to exert an excellent elasticity-enhancing effect via moisturization by directly applying it onto a human skin at a concentration equal to or higher than a predetermined level.  <P>COPYRIGHT: (C)2004,JPO
External cues and contexts contribute to the development of smoking and the use of other drugs, and drugs themselves can alter the value of conditioned cues. Interestingly, nicotine increases the acquisition of new learning, and has been considered as a "cognitive enhancer". Nicotine also prolongs responding when responding is no longer rewarded, during extinction. Although many studies have examined the effects of drugs on learning (acquisition) and unlearning (extinction) in laboratory animals, few have investigated drug effects on learning in humans. Recently, novel procedures have been developed to study conditioning in humans, pairing initially neutral places with food, money or drugs. The investigators will use one of these procedures, a virtual place conditioning procedure, to study how nicotine affects the acquisition and extinction of conditioned behaviors in humans.
Moxifloxacin hydrochloride was effective in the treatment of community acquired pneumonia (CAP) caused by multi-drug resistant Streptococcus pneumoniae MDRSP* isolates. Of 37 microbiologically evaluable patients with MDRSP isolates, 35 patients (95%) achieved clinical and bacteriological success post-therapy. The clinical and bacteriological success rates based on the number of patients treated are shown in Table 12.   
  
* MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates previously known as PRSP (Penicillin­-resistant S. pneumoniae), and are isolates resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 mcg/mL), 2 nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. 

Not all isolates were resistant to all antimicrobial classes tested. Success and eradication rates are summarized in Table 13.
PURPOSE: To obtain the composition containing a triterpenoid compound or its salt and a carrier for external agents, excellent in the antiphlogistic action, excellent in supply stability and productivity, and useful as an antiphlogistic action. CONSTITUTION: This composition contains a compound of the formula [R<1> is OH (protected with a lower alkyl group); R<2> is hydroxymethyl, lower alkoxymethyl; R<3> is (protected)carboxyl] or its salt and a carrier for external agents. The compound of the formula is obtained, e.g. by extracting the roots of Paeonia albiflora with supercritical or high pressure state carbon dioxide, developing the extract containing the compound of the formula in an adsorption column chromatograph. and subsequently developing the adsorption column supercritical or high pressure state carbon dioxide containing ethanol in different concentrations to separate and purify the compound. The objective composition is administered at a dose of 1.0-5.0mg/kg body once for an adult and at a dose of <=5.0mg/kg body a day for an adult as the compound of the formula.